| 1 |
BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: A cancer journal for clinicians,2024, 74(3): 229-263.
|
| 2 |
SIEGEL R L, GIAQUINTO A N, JEMAL A. Cancer statistics, 2024[J].CA: A cancer journal for clinicians, 2024, 74(1): 12-49.
|
| 3 |
ABBAS N F, AOUDE M R, KOURIE H R, et al. Uncovering the epidemiology of bladder cancer in the Arab world: A review of risk factors, molecular mechanisms, and clinical features[J]. Asian journal of urology, 2024, 11(3): 406-422.
|
| 4 |
ANTONI S, FERLAY J, SOERJOMATARAM I, et al. Bladder cancer incidence and mortality: A global overview and recent trends[J].European urology, 2017, 71(1): 96-108.
|
| 5 |
韩苏军, 张思维, 陈万青, 等. 中国膀胱癌发病现状及流行趋势分析[J]. 癌症进展, 2013, 11(1): 89-95.
|
| 6 |
SYLVESTER R J, OOSTERLINCK W, HOLMANG S, et al.Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: Which patients benefit from the instillation?[J]. European urology, 2016, 69(2): 231-244.
|
| 7 |
于浩, 林天歆, 李响, 等. 卡介苗预防中、高危非肌层浸润性膀胱癌术后复发的有效性、安全性随机、对照、多中心临床试验中期报告[J]. 中华泌尿外科杂志, 2019, 40(7): 485-491.
|
| 8 |
孙颖浩. 吴阶平泌尿外科学[M]. 北京：人民卫生出版社, 2019:1236.
|
| 9 |
WANG L, CHARD D L S, CHENG Z, et al. Remodeling the tumor microenvironment by oncolytic viruses: Beyond oncolysis of tumor cells for cancer treatment[J]. Journal for immunotherapy of cancer,2022,10(5): e004167.
|
| 10 |
GRANDI P, DARILEK A, MOSCU A, et al. Intravesical infusion of oncolytic virus CG0070 in the treatment of bladder cancer[J]. Methods in molecular biology, 2023, 2684: 303-317.
|
| 11 |
BURKE J M, LAMM D L, MENG M V, et al. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer[J]. The journal of urology, 2012, 188(6): 2391-2397.
|
| 12 |
PACKIAM V T, LAMM D L, BAROCAS D A, et al. An open label,single-arm, phase Ⅱ multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results[J]. Urologic oncology, 2018, 36(10): 440-447.
|
| 13 |
GLASS M, BUSCHE A, WAGNER K, et al. Conditional and reversible disruption of essential herpesvirus proteins[J]. Nature methods, 2009, 6(8): 577-579.
|
| 14 |
JOO K J, LI H, ZHANG X, et al. Therapeutic effect on bladder cancer with a conditionally replicating oncolytic virus derived from type Ⅱherpes simplex virus[J]. Bladder cancer, 2015, 1(1): 81-90.
|
| 15 |
CZERNIAK B, COHEN G L, ETKIND P, et al. Concurrent mutations of coding and regulatory sequences of the Ha-ras gene in urinary bladder carcinomas[J]. Human pathology, 1992, 23(11): 1199-1204.
|
| 16 |
KOHNO S, LUO C, GOSHIMA F, et al. Herpes simplex virus type 1 mutant HF10 oncolytic viral therapy for bladder cancer[J]. Urology,2005, 66(5): 1116-1121.
|
| 17 |
SHMULEVITZ M, MARCATO P, LEE P W. Unshackling the links between reovirus oncolysis, Ras signaling, translational control and cancer[J]. Oncogene, 2005, 24(52): 7720-7728.
|
| 18 |
GUMMERSHEIMER S L, SNYDER A J, DANTHI P. Control of capsid transformations during reovirus entry[J]. Viruses, 2021, 13(2):153.
|
| 19 |
HANEL E G, XIAO Z, WONG K K, et al. A novel intravesical therapy for superficial bladder cancer in an orthotopic model: Oncolytic reovirus therapy[J]. The journal of urology, 2004, 172(5 Pt 1): 2018-2022.
|
| 20 |
LIM Y, PARK J, LIM J E, et al. Evaluating a combination treatment of NK cells and reovirus against bladder cancer cells using an in vitro assay to simulate intravesical therapy[J]. Scientific reports, 2024,14(1): 7390.
|
| 21 |
MELL L K, BRUMUND K T, DANIELS G A, et al. Phase Ⅰ trial of intravenous oncolytic vaccinia virus (GL-ONC1) with cisplatin and radiotherapy in patients with locoregionally advanced head and neck carcinoma[J]. Clinical cancer research: An official journal of the American Association for Cancer Research, 2017, 23(19): 5696-5702.
|
| 22 |
PARK S H, BREITBACH C J, LEE J, et al. Phase 1b trial of biweekly intravenous Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus in colorectal cancer[J]. Molecular therapy: The journal of the American Society of Gene Therapy, 2015, 23(9): 1532-1540.
|
| 23 |
GOMELLA L G, MASTRANGELO M J, MCCUE P A, et al. PhaseⅠ study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer[J]. The journal of urology, 2001, 166(4): 1291-1295.
|
| 24 |
POTTS K G, IRWIN C R, FAVIS N A, et al. Deletion of F4L(ribonucleotide reductase) in vaccinia virus produces a selective oncolytic virus and promotes anti-tumor immunity with superior safety in bladder cancer models[J]. EMBO molecular medicine, 2017, 9(5):638-654.
|
| 25 |
SHAFREN D R, AU G G, NGUYEN T, et al. Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, Coxsackievirus a21[J]. Clinical cancer research: An official journal of the American Association for Cancer Research,2004, 10(1 Pt 1): 53-60.
|
| 26 |
AU G G, LINDBERG A M, BARRY R D, et al. Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21[J].International journal of oncology, 2005, 26(6): 1471-1476.
|
| 27 |
BERRY L J, AU G G, BARRY R D, et al. Potent oncolytic activity of human enteroviruses against human prostate cancer[J]. The prostate,2008, 68(6): 577-587.
|
| 28 |
SKELDING K A, BARRY R D, SHAFREN D R. Systemic targeting of metastatic human breast tumor xenografts by Coxsackievirus A21[J]. Breast cancer research and treatment, 2009, 113(1): 21-30.
|
| 29 |
AU G G, LINCZ L F, ENNO A, et al. Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma[J]. British journal of haematology, 2007, 137(2): 133-141.
|
| 30 |
RELPH K, ANNELS N, SMITH C, et al. Oncolytic immunotherapy for bladder cancer using Coxsackie A21 virus: Using a bladder tumor precision-cut slice model system to assess viral efficacy[J]. Methods in molecular biology, 2020, 2058: 249-259.
|